Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.62 |
| ▸ | RET | P07949 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 3/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359307 | 0.89 | PDGFRB (0.71) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5364624 | 0.87 | PDGFRB (0.69) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5359118 | 0.87 | FLT3 (0.68) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5365979 | 0.85 | FLT3 (0.66) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5373629 | 0.85 | PDGFRB (0.76) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5363278 | 0.83 | PDGFRB (0.68) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL19255670 | 0.82 | PDGFRB (0.77) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5360816 | 0.81 | PDGFRB (0.62) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5365610 | 0.81 | PDGFRB (0.69) | FLT3PDGFRBRETFGFR1ALK | |
| SCHEMBL5376617 | 0.80 | PDGFRB (0.74) | FLT3PDGFRBRETFGFR1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486185-B1 | 3-heteroarylidene-2-indolinone protein kinase inhibitors | SUGEN, INC. | 2002-11-26 | — | — | US | claimed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6683082-B2 | 3-HETERO-ARYLIDENE-2-INDOLINONE COMPOUNDS; ANTICANCER AGENTS | SUGEN, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6486185-B1 | 3-heteroarylidene-2-indolinone protein kinase inhibitors | SUGEN, INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020156083-A1 | Bicyclic protein kinase inhibitors | TANG PENG CHO (US) | 2002-10-24 | — | — | US | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | FLT3 835/4885PDGFRB 1754/4885RET 518/4885 |
| US-20020156083-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K2, MAP4K3 | FLT3 718/4885PDGFRB 1479/4885RET 479/4885 |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | FLT3 835/4885PDGFRB 1754/4885RET 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.